Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(6 sites)

United States

Boston Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

NYU Langone Hospital - Long Island, Mineola, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee